State Street SPDR S&P Pharmaceuticals ETF
XPHDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 24, 2026 | $0.06 | 2026-06-22 | 2026-06-22 |
| March 25, 2026 | $0.06 | 2026-03-23 | 2026-03-23 |
| December 24, 2025 | $0.11 | 2025-12-22 | 2025-12-22 |
| September 24, 2025 | $0.10 | 2025-09-22 | 2025-09-22 |
| June 25, 2025 | $0.10 | 2025-06-23 | 2025-06-23 |
Dividends Summary
- Consistent Payer: State Street SPDR S&P Pharmaceuticals ETF has rewarded shareholders with 86 dividend payments over the past 19 years.
- Total Returned Value: Investors who held XPH shares during this period received a total of $19.27 per share in dividend income.
- Latest Payout: The most recent dividend of $0.06/share was paid 24 days ago, on June 24, 2026.
- Yield & Schedule: XPH currently pays dividends quarterly with an annual yield of 0.49%.
- Dividend Growth: Since 2007, the dividend payout has decreased by 61.2%, from $0.15 to $0.06.
Company News
The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (...
The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility...
The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated...
Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opport...
Prestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow...
